325 results
8-K
EX-99.1
INVA
Innoviva Inc
13 May 24
Corporate Presentation May 2024
9:27am
treatments that do not act directly on the heart due to safety concerns 70% 23% Increase in Mean Arterial Pressure Response 1 In a pivotal trial, GIAPREZA
8-K
EX-99.1
INVA
Innoviva Inc
6 Nov 23
Regulation FD Disclosure
8:30am
) in participants who had a positive culture for gonorrhea at baseline. Secondary analyses were microbiological cure at rectal or pharyngeal sites and safety … cure at rectal or pharyngeal sites at TOC (day 6 “ 2); safety Oral dose zoliflodacin (3g) Ceftriaxone IM injection (500mg) + oral azithromycin (1g
8-K
EX-99.1
7849c14gfc
1 Nov 23
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:30pm
8-K
EX-99.1
l9957y
24 May 23
Corporate Presentation May 2023
5:18pm
8-K
EX-99.1
617wydhb3g1gt4d6ogm
9 Nov 22
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:17pm
8-K
EX-99.1
28kb4bqqit9ls6dz
23 Aug 22
Other Events
4:08pm
8-K
EX-10.1
r877wf0lrhmmy
13 Jul 22
Entry into a Material Definitive Agreement
5:27pm
SC TO-C
EX-2.1
zmior2gte0
11 Jul 22
Information about tender offer
3:46pm
8-K
EX-2.1
ko3xs5zbzpc6b0m
11 Jul 22
Innoviva to Acquire La Jolla Pharmaceutical Company
7:38am
425
r3hsicp
11 Jul 22
Business combination disclosure
7:38am
SC TO-C
EX-2.1
63ls70859v37hr
23 May 22
Information about tender offer
8:53pm
8-K
EX-2.1
5gum60l 6ys2n
23 May 22
Tender and Support Agreement
8:51pm